BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

11 articles for L Öster

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kd inhibitors.EBI
Astrazeneca
Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.EBI
Astrazeneca
Discovery of a novel pyrazole series of group X secreted phospholipase A2 inhibitor (sPLA2X) via fragment based virtual screening.EBI
Astrazeneca
Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats.EBI
Astrazeneca Research and Development
Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa.EBI
Griffith University
Discovery and Characterization of a Bicyclic Peptide (Bicycle) Binder to Thymic Stromal Lymphopoietin.EBI
BicycleTx Limited
Discovery and optimization of cyclohexane-1,4-diamines as allosteric MALT1 inhibitors.EBI
Astrazeneca
Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma.EBI
Astrazeneca
Fragment-Based Discovery of Novel Allosteric MEK1 Binders.EBI
Astrazeneca
Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors.EBI
Pharmaron-Beijing
Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration.EBI
Astrazeneca